Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer

OBJECTIVES:

Primary

• To assess the complete and overall response rate of neoadjuvant docetaxel, cisplatin, fluorouracil, and leucovorin calcium in previously untreated patients with local regionally advanced head and neck cancer.
• To evaluate the feasibility of a multimodality treatment approach with the goal of reducing long-term sequelae.
• To evaluate prospectively, the impact of neoadjuvant chemotherapy, concurrent chemoradiotherapy, and organ preservation surgery on overall survival, time to progression, and pattern of disease recurrence in these patients.
• To evaluate prospectively, biochemical correlates of response and prognosis, including markers such as thymidylate synthetase, ribonucleotide reductase, and ERCC1 (measured by quantitative PCR), p53 (evaluated by IHC), and HPV status and apoptosis (TUNEL assay).

Secondary

• To evaluate treatment-associated morbidity with the use of a quality of life assessment tool.
• To compare the results of diagnostic salivary cytology with those of histopathology at initial diagnosis as well as follow-up in head and neck cancer patients.
• To evaluate the tolerability of combined chemoradiotherapy using gemcitabine and cisplatin after definitive surgery for squamous cell carcinoma of the head and neck.

OUTLINE: Patients receive neoadjuvant induction chemotherapy comprising docetaxel IV over 1 hour on day 1 and cisplatin IV, leucovorin IV, and fluorouracil IV over 24 hours on days 1-4. Induction chemotherapy repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.

Patients with partial response at the primary site may undergo radical or functional resection of the primary tumor within 3 weeks of completion of neoadjuvant therapy.

Beginning within 4 weeks of completion of neoadjuvant therapy, patients with persistent disease or complete response after chemotherapy at the primary or neck then undergo radiotherapy 5 days a week for 7 weeks and receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV over 60 minutes on day 1 of each week of radiotherapy in the absence of disease progression or unacceptable toxicity.

Patients complete the FACT-H&N quality of life questionnaire at baseline and at completion of neoadjuvant therapy.

Tissue biopsies are collected at baseline, periodically during therapy, at surgery, and after radiotherapy. Tissue is examined for gene and protein expression.

DISEASE CHARACTERISTICS:

• Histologically confirmed squamous cell carcinoma of the head and neck, including any of the following subtypes:

• Oral cavity
• Oropharynx
• Hypopharynx
• Larynx
• Stage III or IV disease

• Stage II carcinoma of the larynx, hypopharynx, or base of tongue allowed
• Measurable disease
• Resectable disease, defined as tumors that are potentially curable by surgery and radiotherapy

PATIENT CHARACTERISTICS:

• Karnofsky performance status ≥ 60%
• ANC ≥ 1,500/μL
• Platelet count ≥ 100,000/μL
• Creatinine ≤ 1.5 mg/dL OR creatinine clearance > 60 mL/min
• Bilirubin ≤ 1.5 mg/dL
• Transaminases and alkaline phosphatase meeting 1 of the following criteria:

• ALT or AST ≤ 2.5 times upper limit of normal (ULN) AND alkaline phosphatase normal
• Alkaline phosphatase ≤ 4 times ULN AND ALT and AST normal
• ALT or AST < 1.5 times ULN AND alkaline phosphatase < 2.5 times ULN
• Free of serious infection
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No prior malignancy allowed for purposes of determining disease-free or overall survival except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease free for 5 years
• No unstable angina, history of congestive heart failure, or acute myocardial infarction within the past 6 months
• No current symptomatic, neurosensory or neuromotor toxicity ≥ grade 2
• No other significant medical or psychiatric condition incompatible with the protocol

PRIOR CONCURRENT THERAPY:

• No prior chemotherapy or radiotherapy for head and neck cancer